ACTRN12620000346976已完成1 期
A single dose, randomized, open-label, pharmacokinetic study of a generic formulation of 5/2.5 mg s 4,5a-epoxy14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride/naloxone tablet in a 2 way crossover comparison against the innovator 5/2.5 mg s 4,5a-epoxy14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride/naloxone tablet conducted under fed conditions in healthy volunteers.
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •Healthy males and non-pregnant females
- •Aged between 18 and 55 years
- •Non-smoker
- •BMI greater than or equal to 18.5 and less than 32 inclusive
- •Normal, healthy individuals as determined by medical history, physical examination, ECG, blood pressure and laboratory tests
- •Drug free as determined by urine drug testing
- •Able to comply with the study restrictions
- •Able to provide written informed consent
排除标准
- •Clinically significant medical conditions
- •History of conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug
- •History of alcohol or drug abuse or dependency
- •Participation in a drug study within 30 days of the start of the study
- •Sensitivitie to the study drug or excipients
- •Individuals for whom the Clinical Investigator believes, for any reason, that participation would not be an acceptable risk
研究者
相似试验
已完成
1 期
Comparative assessment of the absorption of a generic formulation of 5/2.5 mg s 4,5a-epoxy14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride/naloxone tablet against the innovator 5/2.5 mg s 4,5a-epoxy14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride/naloxone tablet conducted under fasting conditions in healthy volunteers.ACTRN12620000327987Zenith Technology Corporation Limited26
已完成
1 期
Comparative assessment of the absorption of a test formulation of 1 x 30 mg isotretinoin capsule against the innovator 1 x 30 mg isotretinoin capsule conducted under fed conditions in healthy male volunteers.Isotretinoin is a medicine that is used to treat severe forms of acne.Skin - Dermatological conditionsACTRN12618000935235Zenith Technology Corporation Limited32
已完成
1 期
Comparative assessment of the absorption of a test formulation of 1 x 40 mg isotretinoin capsule against the innovator 1 x 40 mg isotretinoin capsule conducted under fed conditions in healthy male volunteers.Isotretinoin is a medicine that is used to treat severe forms of acne.Skin - Dermatological conditionsACTRN12619000154101Zenith Technology Corp Ltd42
已完成
1 期
Comparative assessment of the absorption of a test formulation of 1 x 30 mg isotretinoin capsule against the innovator 1 x 30 mg isotretinoin capsules conducted under fasting conditions in healthy male volunteers.Isotretinoin is a medicine that is used to treat severe forms of acne.Skin - Dermatological conditionsACTRN12617001407381Zenith Technology Corp Ltd46
已完成
1 期
Comparative assessment of the absorption of a generic formulation of 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule against the innovator 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule conducted under fasting conditions in healthy male volunteers.ACTRN12619001352190Zenith Technology Corporation Limited31